Equities research analysts at RBC Capital hoisted their price target on shares of Celgene Corp. (NASDAQ:CELG) from $145.00 to $150.00 in a research note issued to investors on Friday, Stock Ratings Network.com reports. The firm currently has an “outperform” rating on the stock. RBC Capital’s price objective indicates a potential upside of 4.21% from the stock’s previous close.
Celgene Corp. (NASDAQ: CELG) traded down 0.67% on Friday, hitting $142.98. Celgene Corp. has a 52-week low of $66.87 and a 52-week high of $144.15. The stock’s 50-day moving average is currently $124.8. The company has a market cap of $59.640 billion and a price-to-earnings ratio of 40.25.
Celgene Corp. (NASDAQ:CELG) last announced its earnings results on Thursday, July 25th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.08. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter last year, the company posted $1.22 earnings per share. Celgene Corp.’s revenue was up 17.0% compared to the same quarter last year. On average, analysts predict that Celgene Corp. will post $5.90 earnings per share for the current fiscal year.
A number of other firms have also recently commented on CELG. Analysts at JMP Securities raised their price target on shares of Celgene Corp. from $150.00 to $160.00 in a research note to investors on Friday. They now have a “market outperform” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Celgene Corp. from $152.00 to $161.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Brean Capital raised their price target on shares of Celgene Corp. from $150.00 to $153.00 in a research note to investors on Friday. They now have a “buy” rating on the stock.
Six research analysts have rated the stock with a hold rating and twenty-five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $140.96.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.